Latest news
Rule 10b5-1 plan drives Moderna, Inc. (NASDAQ: MRNA) CEO stock sales - Stock TitanStock Titan · Fri, 07 Aug 2026 20:12:01 GMTModerna reports stronger outlook as pipeline advances and losses narrow - Indian Pharma PostIndian Pharma Post · Wed, 05 Aug 2026 09:31:14 GMTModerna vaccinates first participants in trial for Ebola strain with no vaccine - Stock TitanStock Titan · Tue, 04 Aug 2026 15:00:00 GMTModerna Reports $145 Million Q2 Revenue and $782 Million Net Loss - Quiver QuantitativeQuiver Quantitative · Fri, 31 Jul 2026 11:10:00 GMTModerna (NASDAQ: MRNA) Q2 2026 loss, trims 2026 spending - Stock TitanStock Titan · Fri, 31 Jul 2026 11:04:17 GMTModerna Reports Second Quarter 2026 Financial Results and Provides Business Updates - ACCESS NewswireACCESS Newswire · Fri, 31 Jul 2026 11:03:20 GMTModerna Reports Second Quarter 2026 Financial Results and Provides Business Updates - Eagle-TribuneEagle-Tribune · Fri, 31 Jul 2026 11:01:44 GMTModerna's Flu Vaccine Could Become Its Fifth Approved Product - Stock TitanStock Titan · Fri, 31 Jul 2026 07:00:00 GMT